# Zinc Depletion Increases Susceptibility to AMPK-Induced Atrophic Responses in C2C12 Myotubes

**Authors:** Taishi Imoto, Junpei Ishizaka, Yukinori Tamura

PMC · DOI: 10.3390/pathophysiology33010012 · Pathophysiology · 2026-02-02

## TL;DR

Zinc deficiency makes muscle cells more vulnerable to atrophy caused by AMPK activation, despite not affecting AMPK itself.

## Contribution

The study reveals that zinc availability modulates downstream atrophic responses to AMPK signaling in muscle cells.

## Key findings

- Zinc-depleted cells showed greater atrophy and increased expression of atrophy-related genes after AMPK activation.
- Zinc supplementation increased intracellular zinc levels and altered zinc transporter expression in response to AMPK activation.
- AMPK activation levels were similar across zinc conditions, but downstream effects varied with zinc status.

## Abstract

Background: AMP-activated protein kinase (AMPK) acts as a key energy sensor that negatively regulates skeletal muscle mass. Zinc is an essential trace element that is required for myogenic differentiation and protein synthesis, while zinc deficiency has been associated with muscle atrophy in vivo. However, how zinc status modulates AMPK activation itself or alters downstream responses to AMPK signaling in muscle cells remains unclear. Methods: C2C12 myotubes were cultured under zinc-depleted (ZnD), zinc-sufficient (20 μM; Zn20), or zinc-supplemented (40 μM; Zn40) conditions. AMPK was activated by AICAR, and zinc status–dependent responses were evaluated using molecular and morphological analyses. Results: AICAR increased intracellular zinc levels in Zn20 and Zn40 but not in ZnD. Zinc transporter expression exhibited gene-specific regulation: Zip3 was upregulated across all zinc conditions, Zip14 was significantly induced in ZnD and Zn40, and Zip10 was selectively upregulated in Zn40. AICAR induced myotube atrophy in all groups; however, the reduction in myotube diameter was significantly greater under zinc-depleted conditions. Zinc depletion was associated with transcriptional upregulation of FoxO1, FoxO3, Atrogin-1, and MuRF1 in response to AICAR, while AMPK activation and suppression of S6K1 phosphorylation occurred to a similar extent regardless of zinc status. Conclusions: These findings indicate that zinc availability does not alter AMPK activation itself but modulates downstream atrophic responses to AMPK signaling. Under conditions of AMPK activation, adequate zinc availability is accompanied by increased intracellular zinc levels and stress-responsive ZIP regulation, which may limit excessive atrophic gene induction, whereas zinc depletion increases susceptibility to AMPK-induced atrophic responses in skeletal muscle cells.

## Linked entities

- **Genes:** PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562], SQSTM1 (sequestosome 1) [NCBI Gene 8878], SLC39A14 (solute carrier family 39 member 14) [NCBI Gene 23516], SLC39A10 (solute carrier family 39 member 10) [NCBI Gene 57181], FOXO1 (forkhead box O1) [NCBI Gene 2308], FOXO3 (forkhead box O3) [NCBI Gene 2309], Fbxo32 (F-box protein 32) [NCBI Gene 67731], TRIM63 (tripartite motif containing 63) [NCBI Gene 84676], RPS6KB1 (ribosomal protein S6 kinase B1) [NCBI Gene 6198]
- **Proteins:** RPS6KB1 (ribosomal protein S6 kinase B1)
- **Chemicals:** Zinc (PubChem CID 23994), AICAR (PubChem CID 65110)

## Full-text entities

- **Genes:** SLC39A4 (solute carrier family 39 member 4) [NCBI Gene 55630] {aka AEZ, AWMS2, ZIP4}, SLC39A3 (solute carrier family 39 member 3) [NCBI Gene 29985] {aka ZIP-3, ZIP3}, SLC39A14 (solute carrier family 39 member 14) [NCBI Gene 23516] {aka HCIN, HMNDYT2, LZT-Hs4, NET34, ZIP14, cig19}, MAP1LC3A (microtubule associated protein 1 light chain 3 alpha) [NCBI Gene 84557] {aka ATG8E, LC3, LC3A, MAP1ALC3, MAP1BLC3}, ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase) [NCBI Gene 471] {aka AICAR, AICARFT, HEL-S-70p, IMPCHASE, PURH}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, FBXO32 (F-box protein 32) [NCBI Gene 114907] {aka Fbx32, MAFbx}, SLC39A1 (solute carrier family 39 member 1) [NCBI Gene 27173] {aka ZIP1, ZIRTL}, TRIM63 (tripartite motif containing 63) [NCBI Gene 84676] {aka CMH31, IRF, MURF1, MURF2, RNF28, SMRZ}, PRL (prolactin) [NCBI Gene 5617] {aka GHA1, pPRL}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, FOXO3 (forkhead box O3) [NCBI Gene 2309] {aka AF6q21, FKHRL1, FKHRL1P2, FOXO2, FOXO3A}, DAPK3 (death associated protein kinase 3) [NCBI Gene 1613] {aka DLK, ZIP, ZIPK}, Prkaa2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 78975] {aka Ampk, Ampka2}, PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 5563] {aka AMPK, AMPK2, AMPKa2, PRKAA}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, CAT (catalase) [NCBI Gene 847], SLC39A10 (solute carrier family 39 member 10) [NCBI Gene 57181] {aka LZT-Hs2, ZIP10}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, HMBS (hydroxymethylbilane synthase) [NCBI Gene 3145] {aka ENCEP, LENCEP, PBG-D, PBGD, PORC, UPS}, RPS6KB1 (ribosomal protein S6 kinase B1) [NCBI Gene 6198] {aka PS6K, S6K, S6K-beta-1, S6K1, STK14A, p70 S6KA}, FOXO1 (forkhead box O1) [NCBI Gene 2308] {aka FKH1, FKHR, FOXO1A}
- **Diseases:** cachexia (MESH:D002100), inflammatory or metabolic diseases (MESH:D008659), hypoxia (MESH:D000860), Zinc deficiency (MESH:C564286), injury to (MESH:D014947), inflammation (MESH:D007249), muscle atrophy (MESH:D009133), sarcopenia (MESH:D055948), mitochondrial myopathy (MESH:D017240), mitochondrial dysfunction (MESH:D028361), growth retardation (MESH:D006130), diabetes (MESH:D003920), cancer cachexia (MESH:D009369), Myotube Atrophy (MESH:D001284), muscle loss (MESH:D009135), chronic disease (MESH:D002908), immune dysfunction (MESH:D007154)
- **Chemicals:** SDS (MESH:D012967), methanol (MESH:D000432), Zinc (MESH:D015032), Chelex (MESH:C006960), EDTA (MESH:D004492), streptomycin (MESH:D013307), CO2 (MESH:D002245), Chelex 100 (MESH:C024997), AMP (MESH:D000249), ATP (MESH:D000255), lipid (MESH:D008055), PVDF (MESH:C024865), ZnSO4 (MESH:D019287), glucose (MESH:D005947), Ca2+ (-), penicillin (MESH:D010406), AICAR (MESH:C031143)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** C2C12 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0188)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12922060/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12922060/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12922060/full.md

---
Source: https://tomesphere.com/paper/PMC12922060